Kund, You old softie, your making positive points for the company again, although vailed in that rough exterior you portray to us. Let's see:
Stuck at $6. A real indicator of lack of volatility. Maybe that is based on some real savvy institutions like Blackrock, Vanguard, and Knoll having very capable analysts and bio intelligence sources saying that this little bio may just have something.
The CEO and CFO options don't mean a thing unless there is a positive belief that 1,2, 3 years down the line that the share price will be appreciably elevated. Good point that it will dilute at a much higher price!
Phase 2/3 is not on the board yet but it is bolstered by the ongoing Phase 2, Australian Government funding, and very likely NIA grant from the $400M Alzheimer's Fund. ANAVEX has a plan for for three trials and all three will be conducted under 21st Century Cures Act architecture being formulated at the FDA as we speak. This is all coming together rapidly, Rett Syndrome first, AZ P2/3 second then Parkinson.s and possibly M/S and Epilepsy to follow. Phew! Great foresight on your part!
Yes, Biogen has 2-73 in their lab. As I posted before they are being challenged in their M/S line-up and facing a very expensive P3 with Aducanumab. I believe if I can read your point here...its not whether but how much.
PK/PD and Ariana, what another great point.....the future of drug development....precision medicine!
Finally, you you highlight the patent , what a super final point...protection for 2-73 and avenue for protection of its future multi-uses.
Kund....Great Post.
